Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
Key Insights Vor Biopharma's significant private equity firms ownership suggests that the key decisions are influenced...
Stay updated with breaking news from Robert Ang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Vor Biopharma's significant private equity firms ownership suggests that the key decisions are influenced...
Company-Sponsored Educational Events Will Feature Latest Surgical Technologies, Including the SeeLuma™ Fully Digital Surgical Visualization Platform, MIMS® and the IC-8® Apthera IOL ...
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs... -Today at 04:07 pm- MarketScreener
Investegate announcements from PureTech Health PLC, Vor Announces AML Clinical Data + Raises $115M
This type of stem cell transplant utilizes genetic engineering to spare healthy cells